JP2021517471A5 - - Google Patents

Info

Publication number
JP2021517471A5
JP2021517471A5 JP2020568946A JP2020568946A JP2021517471A5 JP 2021517471 A5 JP2021517471 A5 JP 2021517471A5 JP 2020568946 A JP2020568946 A JP 2020568946A JP 2020568946 A JP2020568946 A JP 2020568946A JP 2021517471 A5 JP2021517471 A5 JP 2021517471A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
composition
acid sequence
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020568946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517471A (ja
JP7419268B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/020404 external-priority patent/WO2019169332A1/en
Publication of JP2021517471A publication Critical patent/JP2021517471A/ja
Publication of JP2021517471A5 publication Critical patent/JP2021517471A5/ja
Priority to JP2024001725A priority Critical patent/JP2024050594A/ja
Application granted granted Critical
Publication of JP7419268B2 publication Critical patent/JP7419268B2/ja
Priority to JP2025283313A priority patent/JP2026067877A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020568946A 2018-03-02 2019-03-01 変異kras配列及び脂質を含む化合物並びにその使用 Active JP7419268B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024001725A JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用
JP2025283313A JP2026067877A (ja) 2018-03-02 2025-12-26 変異kras配列及び脂質を含む化合物並びにその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862637879P 2018-03-02 2018-03-02
US62/637,879 2018-03-02
PCT/US2019/020404 WO2019169332A1 (en) 2018-03-02 2019-03-01 Compounds including a mutant kras sequence and a lipid and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001725A Division JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用

Publications (3)

Publication Number Publication Date
JP2021517471A JP2021517471A (ja) 2021-07-26
JP2021517471A5 true JP2021517471A5 (cg-RX-API-DMAC7.html) 2022-03-09
JP7419268B2 JP7419268B2 (ja) 2024-01-22

Family

ID=67805548

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020568946A Active JP7419268B2 (ja) 2018-03-02 2019-03-01 変異kras配列及び脂質を含む化合物並びにその使用
JP2024001725A Pending JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用
JP2025283313A Pending JP2026067877A (ja) 2018-03-02 2025-12-26 変異kras配列及び脂質を含む化合物並びにその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024001725A Pending JP2024050594A (ja) 2018-03-02 2024-01-10 変異kras配列及び脂質を含む化合物並びにその使用
JP2025283313A Pending JP2026067877A (ja) 2018-03-02 2025-12-26 変異kras配列及び脂質を含む化合物並びにその使用

Country Status (15)

Country Link
US (4) US12138301B2 (cg-RX-API-DMAC7.html)
EP (1) EP3758713A4 (cg-RX-API-DMAC7.html)
JP (3) JP7419268B2 (cg-RX-API-DMAC7.html)
KR (2) KR102787353B1 (cg-RX-API-DMAC7.html)
CN (2) CN112118847B (cg-RX-API-DMAC7.html)
AU (1) AU2019226586B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020017645A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092679A1 (cg-RX-API-DMAC7.html)
IL (1) IL277100B2 (cg-RX-API-DMAC7.html)
MA (1) MA52435A (cg-RX-API-DMAC7.html)
MX (2) MX2020009149A (cg-RX-API-DMAC7.html)
MY (1) MY207748A (cg-RX-API-DMAC7.html)
SA (1) SA520420064B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008433QA (cg-RX-API-DMAC7.html)
WO (1) WO2019169332A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102787353B1 (ko) 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도
US12247052B2 (en) * 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof
US20240123070A1 (en) * 2021-02-10 2024-04-18 Shanghai GenBase Biotechnology Co., Ltd. Epitope peptide of ras g13d mutant and t cell receptor recognizing ras g13d mutant
KR102818249B1 (ko) 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
KR102732910B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732912B1 (ko) 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0895538B1 (en) 1996-04-19 2002-07-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
US7709002B1 (en) 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
JPWO2005001116A1 (ja) 2003-06-17 2006-08-24 明治乳業株式会社 Toll様レセプター強制発現細胞の利用
EP1699920A4 (en) 2003-12-31 2008-05-28 Centocor Inc NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL
EP2155889A4 (en) 2007-05-25 2010-06-16 Centocor Ortho Biotech Inc TOLL RECEPTOR 3 MODULATORS AND USES THEREOF
US20120264810A1 (en) 2009-09-22 2012-10-18 The University Of British Columbia Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles
AU2012209274A1 (en) * 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
JP6375289B2 (ja) 2012-04-05 2018-08-15 マサチューセッツ インスティテュート オブ テクノロジー 免疫刺激組成物およびその使用方法
JP6283661B2 (ja) * 2012-05-09 2018-02-21 ストライク バイオ インク.Strike Bio,Inc. 一塩基KRAS変異に特異的な二機能性低分子ヘアピン型RNA(BI−SHRNA,Bi−functionalShort−HairpinRNA)
AU2013291125A1 (en) 2012-07-16 2015-01-22 Dicerna Pharmaceuticals, Inc. RNAi pharmaceutical composition capable of suppressing expression of KRAS gene
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
KR102100289B1 (ko) 2013-10-24 2020-04-13 주식회사 다이셀 은 나노 입자 함유 분산액의 제조 방법 및 은 나노 입자 함유 분산액
AU2015314763A1 (en) 2014-09-11 2017-04-06 Vedantra Pharmaceuticals, Inc. Multilamellar lipid vesicle compositions and methods of use
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
US10619159B2 (en) * 2016-01-19 2020-04-14 The University Of North Carolina At Chapel Hill Methods and compositions using RNA interference for inhibition of KRAS
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
EP3585428A1 (en) 2017-02-23 2020-01-01 Alpha-o Peptides AG Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
TW201919712A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 運送子(cargomers)
KR102787353B1 (ko) 2018-03-02 2025-03-26 엘리시오 테라퓨틱스, 인크. 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도
US12247052B2 (en) 2018-03-02 2025-03-11 Elicio Therapeutics, Inc. CpG amphiphiles and uses thereof

Similar Documents

Publication Publication Date Title
JP7419268B2 (ja) 変異kras配列及び脂質を含む化合物並びにその使用
JP2021533800A (ja) 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用
HUE027064T2 (hu) Fokozott immunstimuláns aktivitású, hidrofób T-analógokat tartalmazó CPG oligonukleotid-analógok
FR2814958A1 (fr) Composition vaccinale
JP2024045151A (ja) Cpgアンフィフィル及びその使用
EP1625850B1 (en) Immunostimulating agents
JP2023532290A5 (cg-RX-API-DMAC7.html)
CA2980329A1 (en) Self assembling molecules for targeted drug delivery
WO2024169907A1 (zh) 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途
NZ768282B2 (en) Compounds including a mutant kras sequence and a lipid and uses thereof
JP2014198711A (ja) Ct阻害4価ペプチドおよびコレラ治療薬
TH2001004948A (th) สารประกอบที่รวมถึงลำดับ kras พันธุ์กลาย และไขมันและการใช้ของสารประกอบนั้น
RU2823677C2 (ru) Cpg амфифилы и их применения
HK40043265B (en) Compounds including a mutant kras sequence and a lipid and uses thereof
WO2021132528A1 (ja) ポリデオキシアデニル酸が連結した短鎖CpG含有オリゴデオキシヌクレオチド、該オリゴデオキシヌクレオチドを含有する複合体、及びその用途
HK40045177A (en) Cpg amphiphiles and uses thereof
HK40045177B (en) Cpg amphiphiles and uses thereof
WO2021193900A1 (ja) ポリヌクレオチド-ペプチドコンジュゲートを含む免疫誘導剤およびそれを含む医薬組成物
HK40043266A (en) Cpg amphiphiles and uses thereof